Hoth Therapeutics Files Q1 2024 10-Q Report

TL;DR

HOTH filed its Q1 2024 10-Q. All systems go from NY HQ.

AI Summary

Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2024. The company, incorporated in Nevada, is involved in the pharmaceutical preparations industry. Its principal executive offices are located at 590 Madison Avenue, New York, NY.

Why It Matters

This filing provides investors with an update on Hoth Therapeutics' financial performance and operational status for the first quarter of 2024.

Risk Assessment

Risk Level: low — This is a standard quarterly filing and does not contain immediate, high-impact news.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• March 31, 2024 (date) — Quarterly Period End Date
• 590 Madison Avenue, 21st Floor, New York, NY 10022 (location) — Principal Executive Offices
• 001-38803 (other) — Commission File Number

FAQ

From the Filing

0001213900-24-042906.txt : 20240514 0001213900-24-042906.hdr.sgml : 20240514 20240514160056 ACCESSION NUMBER: 0001213900-24-042906 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 24944046 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 10-Q 1 ea0204707-10q_hoththerap.htm QUARTERLY REPORT     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  10-Q   (Mark One)   ☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the Quarterly Period Ended: March 31, 2024   ☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from:   Commission File Number: 001-38803   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   82-1553794 (State or other jurisdiction of   (I.R.S. Employer incorporation or organization)   Identification No.)   590 Madison Ave ., 21 st Floor New York , NY   10022 (Address of principal executive offices)   (Zip Code)   Issuer’s telephone number: (646) 756-2997   Not applicable (Former name, former address and former fiscal year, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒     Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒   The number of shares of the issuer’s common stock, $0.0001 par value per s